2. Academic Validation
  3. Granulocyte colony-stimulating factor in traumatic spinal cord injury

Granulocyte colony-stimulating factor in traumatic spinal cord injury

  • Drug Discov Today. 2021 Jul;26(7):1642-1655. doi: 10.1016/j.drudis.2021.03.014.
Stephanie Aschauer-Wallner 1,  Stefan Leis 2,  Ulrich Bogdahn 3,  Siw Johannesen 4,  Sebastien Couillard-Despres 5,  Ludwig Aigner 6
Affiliations

Affiliations

  • 1 Department of Orthopedics and Traumatology, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria. Electronic address: [email protected].
  • 2 Department of Neurology, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • 3 Velvio GmbH, Regensburg, Germany; Department of Neurology, University Hospital Regensburg, Regensburg, Germany.
  • 4 Department of Neurology, University Hospital Regensburg, Regensburg, Germany; Department of Neurology, BG Trauma Center Murnau, Murnau, Germany.
  • 5 Institute of Experimental Neuroregeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Austrian Cluster for Tissue Regeneration, Vienna, Austria.
  • 6 Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria; Austrian Cluster for Tissue Regeneration, Vienna, Austria.
PMID: 33781952 DOI: 10.1016/j.drudis.2021.03.014
Abstract

Granulocyte colony-stimulating factor (G-CSF) is a cytokine used in pharmaceutical preparations for the treatment of chemotherapy-induced neutropenia. Evidence from experimental studies indicates that G-CSF exerts relevant activities in the central nervous system (CNS) in particular after lesions. In acute, subacute, and chronic CNS lesions, G-CSF appears to have strong anti-inflammatory, antiapoptotic, antioxidative, myelin-protective, and axon-regenerative activities. Additional effects result in the stimulation of angiogenesis and neurogenesis as well as in bone marrow stem cell mobilization to the CNS. There are emerging preclinical and clinical data indicating that G-CSF is a safe and effective drug for the treatment of acute and chronic traumatic spinal cord injury (tSCI), which we summarize in this review.

Keywords

G-CSF; Neuroregeneration; Orphan diseases; SCI treatment; Traumatic SCI.

Figures